BioSpace News Archive

Immatics N.V. provided a business update and reported financial results for the quarter and full year ended December 31, 2023.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival and progression-free survival for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer.

InflaRx N.V. announced its financial and operating results for the year ended December 31, 2023, and provided a comprehensive strategic update on its future development and operational plans.

Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors.

Gyre Therapeutics today announced the appointment of Rodney L. Nussbaum to the Company’s Board of Directors and as a member of its Audit Committee.

MiNK Therapeutics, Inc. announced results for the fourth quarter and full-year 2023.

ScienceMedia, a global SaaS provider redefining the landscape of clinical mastery in the biotech and pharma industries, announces the formation of its inaugural advisory board.

Alpine Immune Sciences, Inc. announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.

Daré Bioscience, Inc. today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update.

CytomX Therapeutics, Inc. today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.